AngioGenex

Patents

The current patent portfolio for AngioGenex is:

• Notice-of allowance received from USPTO for AGX-51 patent
• Four AGX-owned Small Molecule Patents Pending
  • Other Id Inhibitor Compounds and Structures Covered by AngioGenex Owned Patent Pending
• One AGX-owned Patent Pending re Methods for Measuring Id Proteins in Biologic Fluids Like Blood 
• Two Jointly-owned AGX/BioCheck Patents Pending for Id1 & Id3 Antibodies.
  • AGX has Rights to the Id1 and Id3 Monoclonal Antibodies for Therapeutic Use 
  • BioCheck has Rights for Development of Id-based Diagnostics with Milestones and Royalties Contracted to AGX.
• Also, Multiple Trade Secrets in the Id Field